A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero
We aimed to evaluate the safety of maternal Tdap; thus, we assessed health events by examining the difference in birth and hospital-related outcomes of infants with and without fetal exposure to Tdap. This was a retrospective cohort study using linked administrative datasets. The study population we...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/7/4/147 |
| _version_ | 1828372271548334080 |
|---|---|
| author | Helen Petousis-Harris Yannan Jiang Lennex Yu Donna Watson Tony Walls Nikki Turner Anna S. Howe Jennifer B. Griffin |
| author_facet | Helen Petousis-Harris Yannan Jiang Lennex Yu Donna Watson Tony Walls Nikki Turner Anna S. Howe Jennifer B. Griffin |
| author_sort | Helen Petousis-Harris |
| collection | DOAJ |
| description | We aimed to evaluate the safety of maternal Tdap; thus, we assessed health events by examining the difference in birth and hospital-related outcomes of infants with and without fetal exposure to Tdap. This was a retrospective cohort study using linked administrative datasets. The study population were all live-born infants in New Zealand (NZ) weighing at least 400 g at delivery and born to women who were eligible for the government funded, national-level vaccination program in 2013. Infants were followed from birth up to one year of age. There were a total of 69,389 eligible infants in the cohort. Of these, 8299 infants were born to 8178 mothers exposed to Tdap (12%), primarily between 28 and 38 weeks gestation as per the national schedule. Among the outcomes, we found a reduced risk for moderate to late preterm birth, low birth weight, small for gestational age, large for gestational age, respiratory distress syndrome, transient tachypnea of newborn, tachycardia or bradycardia, haemolytic diseases, other neonatal jaundice, anaemia, syndrome of infant of mother with gestational diabetes, and hypoglycemia in infants born to vaccinated mothers. There was no association between maternal Tdap, infant Apgar score at 5 min after birth, asphyxia, sepsis or infection, or hypoxic ischemic encephalopathy. Infant exposure to Tdap during pregnancy was associated with a higher mean birthweight (not clinically significant) and higher odds for ankyloglossia and neonatal erythema toxicum diagnoses. There were insufficient observations to allow examination of the effect of Tdap on extreme preterm and very preterm birth, and stillbirth, infant death, or microcephaly. Overall, we found no outcomes of concern associated with the administration of Tdap during pregnancy. NZ Health and Disability Ethics Committee Approval #14/N.T.A/169/AM05. |
| first_indexed | 2024-04-14T07:01:37Z |
| format | Article |
| id | doaj.art-a530c821a50a4852936a00366e0d737c |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-04-14T07:01:37Z |
| publishDate | 2019-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-a530c821a50a4852936a00366e0d737c2022-12-22T02:06:44ZengMDPI AGVaccines2076-393X2019-10-017414710.3390/vaccines7040147vaccines7040147A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in UteroHelen Petousis-Harris0Yannan Jiang1Lennex Yu2Donna Watson3Tony Walls4Nikki Turner5Anna S. Howe6Jennifer B. Griffin7Vaccine Datalink and Research Group, Department of General Practice & Primary Healthcare, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New ZealandDepartment of Statistics, University of Auckland, Private Bag 92019, Auckland 1142, New ZealandDepartment of Statistics, University of Auckland, Private Bag 92019, Auckland 1142, New ZealandImmunisation Advisory Centre, Department of General Practice & Primary Healthcare, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New ZealandDepartment of Paediatrics, University of Otago, PO Box 4345, Christchurch Mail Centre 8140, New ZealandImmunisation Advisory Centre, Department of General Practice & Primary Healthcare, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New ZealandVaccine Datalink and Research Group, Department of General Practice & Primary Healthcare, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New ZealandSocial, Statistical, and Environmental Sciences, RTI International, 3040 East Cornwallis Road, Research Triangle Park, NC 27709-2194, USAWe aimed to evaluate the safety of maternal Tdap; thus, we assessed health events by examining the difference in birth and hospital-related outcomes of infants with and without fetal exposure to Tdap. This was a retrospective cohort study using linked administrative datasets. The study population were all live-born infants in New Zealand (NZ) weighing at least 400 g at delivery and born to women who were eligible for the government funded, national-level vaccination program in 2013. Infants were followed from birth up to one year of age. There were a total of 69,389 eligible infants in the cohort. Of these, 8299 infants were born to 8178 mothers exposed to Tdap (12%), primarily between 28 and 38 weeks gestation as per the national schedule. Among the outcomes, we found a reduced risk for moderate to late preterm birth, low birth weight, small for gestational age, large for gestational age, respiratory distress syndrome, transient tachypnea of newborn, tachycardia or bradycardia, haemolytic diseases, other neonatal jaundice, anaemia, syndrome of infant of mother with gestational diabetes, and hypoglycemia in infants born to vaccinated mothers. There was no association between maternal Tdap, infant Apgar score at 5 min after birth, asphyxia, sepsis or infection, or hypoxic ischemic encephalopathy. Infant exposure to Tdap during pregnancy was associated with a higher mean birthweight (not clinically significant) and higher odds for ankyloglossia and neonatal erythema toxicum diagnoses. There were insufficient observations to allow examination of the effect of Tdap on extreme preterm and very preterm birth, and stillbirth, infant death, or microcephaly. Overall, we found no outcomes of concern associated with the administration of Tdap during pregnancy. NZ Health and Disability Ethics Committee Approval #14/N.T.A/169/AM05.https://www.mdpi.com/2076-393X/7/4/147post-marketing surveillancevaccine safetypertussistdappregnancyinfant |
| spellingShingle | Helen Petousis-Harris Yannan Jiang Lennex Yu Donna Watson Tony Walls Nikki Turner Anna S. Howe Jennifer B. Griffin A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero Vaccines post-marketing surveillance vaccine safety pertussis tdap pregnancy infant |
| title | A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero |
| title_full | A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero |
| title_fullStr | A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero |
| title_full_unstemmed | A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero |
| title_short | A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero |
| title_sort | retrospective cohort study of safety outcomes in new zealand infants exposed to tdap vaccine in utero |
| topic | post-marketing surveillance vaccine safety pertussis tdap pregnancy infant |
| url | https://www.mdpi.com/2076-393X/7/4/147 |
| work_keys_str_mv | AT helenpetousisharris aretrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT yannanjiang aretrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT lennexyu aretrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT donnawatson aretrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT tonywalls aretrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT nikkiturner aretrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT annashowe aretrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT jenniferbgriffin aretrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT helenpetousisharris retrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT yannanjiang retrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT lennexyu retrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT donnawatson retrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT tonywalls retrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT nikkiturner retrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT annashowe retrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero AT jenniferbgriffin retrospectivecohortstudyofsafetyoutcomesinnewzealandinfantsexposedtotdapvaccineinutero |